Prof John Breitner, Professor of Psychiatry at McGill University.
Why clinical trials fail to validate efficacy of interventions predicted by observational studies of \u2018risks\u2019 for dementia-Alzheimer syndrome?, Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer\u2019s Disease Pathogenesis, and Cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology
\nProf John Breitner is Professor of Psychiatry at McGill University. He is also Director of the Centre for Studies on Prevention of Alzheimer\u2019s Disease at the Douglas Research Centre
\n\n--- \n\nSupport this podcast: https://podcasters.spotify.com/pod/show/scientificsense/support